Journal: Translational Cancer Research

Article Title: Multi-omics analysis of BTF3L4 as a prognostic and immune biomarker in hepatocellular carcinoma

doi: 10.21037/tcr-2025-aw-2179

Figure Lengend Snippet: Representative mIHC images of tumor-infiltrating immune cells and immunoregulatory genes. Representative mIHC images show the fluorescence intensities of the composite of CD3, CD8, CD20, CD68, CD86, CD163, LAMP3, PD-1 and PD-L1 in (A) HCC tissues and (B) adjacent non-tumor tissues. CK, cytokeratin; HCC, hepatocellular carcinoma; mIHC, multiplex immunohistochemistry; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1.

Article Snippet: The following primary antibodies were used: anti-cytokeratin (CK) antibody (1:1,000, Orb69073, Biorbyt, Cambridge, UK), anti-BTF3L4 antibody (1:250, Orb511711, Biorbyt), anti-CD3e antibody (1:3,000, 85061S, CST, Danvers, MA, USA), anti-CD4 antibody (1:100, ab133616, Abcam, Cambridge, UK), anti-CD8 antibody (1:200, 85336S, CST), anti-CD20 antibody (1:200, ab78237, Abcam), anti-CD66b antibody (1:10,000, arg66287, Arigo, Zhubei, China), anti-CD68 antibody (1:10,000, 76437S, CST), anti-CD86 antibody (1:100, MAB1774, R&D Systems, Minneapolis, MN, USA), anti-CD163 antibody (1:100, 93498S, CST), anti-Lamp3 antibody (1:500, ab111090, Abcam), anti-PD-1 antibody (1:500, 86163, CST), anti-PD-L1 antibody (1:100, 13684S, CST), anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) (1:2,000, Orb527271, Biorbyt).

Techniques: Fluorescence, Multiplex Assay, Immunohistochemistry

Journal: Translational Cancer Research

Article Title: Multi-omics analysis of BTF3L4 as a prognostic and immune biomarker in hepatocellular carcinoma

doi: 10.21037/tcr-2025-aw-2179

Figure Lengend Snippet: Correlation of BTF3L4 protein expression with tumor-infiltrating immune cells (TIICs) and immunoregulatory genes in HCC. (A) Heatmap of the association between BTF3L4 protein levels and TIICs as well as immunoregulatory genes. (B-K) Correlation between BTF3L4 protein levels and (B) CD66b + neutrophils, (C) CD4 + T cells (CD3 + CD4 + ), (D) CTLA-4, (E) CD20 + B cells, (F) M1-like macrophages (CD86 + CD68 + ), (G) M2-like macrophages (CD163 + CD68 + ), (H) CD8 + T cells (CD3 + CD8 + ), (I) LAMP3 + dendritic cells, (J) PD-1, and (K) PD-L1 by Spearman correlation analysis. HCC, hepatocellular carcinoma; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1; TIICs, tumor-infiltrating immune cells.

Article Snippet: The following primary antibodies were used: anti-cytokeratin (CK) antibody (1:1,000, Orb69073, Biorbyt, Cambridge, UK), anti-BTF3L4 antibody (1:250, Orb511711, Biorbyt), anti-CD3e antibody (1:3,000, 85061S, CST, Danvers, MA, USA), anti-CD4 antibody (1:100, ab133616, Abcam, Cambridge, UK), anti-CD8 antibody (1:200, 85336S, CST), anti-CD20 antibody (1:200, ab78237, Abcam), anti-CD66b antibody (1:10,000, arg66287, Arigo, Zhubei, China), anti-CD68 antibody (1:10,000, 76437S, CST), anti-CD86 antibody (1:100, MAB1774, R&D Systems, Minneapolis, MN, USA), anti-CD163 antibody (1:100, 93498S, CST), anti-Lamp3 antibody (1:500, ab111090, Abcam), anti-PD-1 antibody (1:500, 86163, CST), anti-PD-L1 antibody (1:100, 13684S, CST), anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) (1:2,000, Orb527271, Biorbyt).

Techniques: Expressing